<DOC>
	<DOC>NCT01704378</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial investigate the the long-term safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPenâ„¢ in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Signed informed consent obtained before any trialrelated activities Completed the trial BIAsp1236 Planned changes in use of any prescription medication that may interfere with glucose regulation Known or suspected allergy to trial products or related products Women who are having the intention of becoming pregnant, or are judged not to be using adequate contraceptive measures Any other significant condition or concomitant disease or any condition that would interfere with participation as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>